Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for ...
Corvus Pharmaceuticals initiates a Phase 3 trial of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL), a disease with no fully approved treatments. Soquelitinib, an ITK inhibitor, aims to offer a safer and more effective alternative to standard chemotherapy.
Related Clinical Trials
Highlighted Terms
Related News
Corvus Pharmaceuticals initiates a Phase 3 trial of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL), a disease with no fully approved treatments. Soquelitinib, an ITK inhibitor, aims to offer a safer and more effective alternative to standard chemotherapy.
Corvus Pharmaceuticals' CRVS shares rose 13.9% after announcing a phase III study of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL). Soquelitinib, an ITK inhibitor, aims to improve progression-free survival (PFS) and overall survival. Corvus' shares have surged 163.4% YTD, contrasting the industry's 1.6% decline.
Corvus Pharmaceuticals initiates Phase 3 trial of soquelitinib for relapsed/refractory peripheral T-cell lymphoma (PTCL), evaluating its efficacy and safety against standard chemotherapy. Soquelitinib, an ITK inhibitor, aims to treat T cell lymphomas, solid tumors, and immune diseases.